These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1848 related articles for article (PubMed ID: 15265969)

  • 1. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
    J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
    Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
    Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U
    J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
    Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
    N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
    Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
    Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
    Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
    Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
    Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
    Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P
    Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.